Markets

Allarity Therapeutics Receives First Contract For Its Development, Validation And Related Laboratory Services From Undisclosed European Biotech Firm

Oct 30, 2026 · 07:46 AM ET· updated 58m ago

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT

Why It Matters

Allarity won its first contract to do lab work for another biotech company. This shows someone believes in their science and skills enough to pay.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ALLR0.89

+0.00 (+0.20%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.